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Background: Falls are associated with poor prognosis in patients with Parkinson’s
disease (PD). Although several factors related to falls were reported in patients with
PD, objective predictors of falls are not identified. We aimed to determine whether
123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy could be a useful biomarker
to predict falls.
Methods: Forty-five patients with PD were enrolled in this study. These subjects were
followed up more than 5 years after MIBG scintigraphy and were divided into two groups:
one with decreased uptake of MIBG and the other without decreased uptake of MIBG.
The cut-off value for the delayed heart-to-mediastinum ratio was 1.8. Kaplan-Meier
analysis and a log-rank test were performed to test the predictive power of MIBG
cardiac scintigraphy for falls. Univariate analysis was selected because we did not have
appropriate data for adjustment, such as motor and cognitive assessment.
Results: The group with decreased uptake of MIBG had a significantly higher incidence
of falls than that without decreased uptake of MIBG (P = 0.022, log-rank test).
Conclusions: Although the limitations of this study were lack of several key factors
including motor and cognitive assessment, MIBG cardiac scintigraphy may be used to
predict falls in patients with PD.
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INTRODUCTION
Falls predict an unfavorable prognosis due to poor motor function in patients with Parkinson’s
disease (PD), which are attributed to considerable factors including motor and non-motor
impairments (1). Although it is not easy to overcome falls, several interventions have been
developed. These include administration of acetylcholinesterase inhibitors (2) or the prodrug of
epinephrine (3), and Tai chi (4) or other types of exercise (5). Early identification of patients at high
risk for falls is essential to ensure that the above interventions are undertaken before the patient is
bed-ridden due to fall-related injury. There is thus a need for the identification of risk factors that
allow prediction of falls.
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In terms of a risk factor for a poor prognosis, 123I-meta-
iodobenzylguanidine (MIBG) cardiac scintigraphy has been
reported to be a predictor of dementia in PD (6). Patients with
PD tend to have reduced uptake of MIBG, although this measure
varies widely (7). We hypothesized that the wide-range of MIBG
uptake might help define subgroups of patients with PD with
difference in prognosis. To test our hypothesis, we investigated
the relationship between MIBG uptake and falls using data from
45 patients with PD at the Tokushima University Hospital.
MATERIALS AND METHODS
Participants
A total of 438 patients with PD were identified from the
medical records of inpatients and outpatients at the Tokushima
University Hospital between April 1st, 2007 and September 30th,
2017. Ultimately, 45 patients who were diagnosed with clinically
established or probable PD according to the internationally
established PD criteria (8), and were followed up for more than
5 years after MIBG evaluation were included in this study. These
patients were divided into two groups: one with decreased uptake
of MIBG [delayed heart-to-mediastinum ratio [H/M ratio] <
1.8], and the other without decreased uptake of MIBG (delayed
H/M ratio≥ 1.8). We considered the following variables: sex, age
at onset, age at MIBG evaluation, disease duration, Hoehn-Yahr
stage, daily levodopa dose at MIBG evaluation, use of dopamine
agonist at MIBG evaluation, severity and frequency of falls, and
follow-up period after MIBG evaluation. Disease duration was
defined as the period from the onset of motor symptoms to
the time of MIBG evaluation. Severe falls were defined by the
need for medical care after injuries. Injuries due to falls and
the number of subjects with injury were summarized in the
Supplementary Table 1. The present study protocol (number
3118) was approved by the local ethical committee at Tokushima
University Hospital in March 2018.
MIBG Imaging
MIBG imaging was performed 15min (early) and 3–4 h (delayed)
after intravenous injection of 123I-MIBG (111 mBq). The H/M
ratio was calculated according to the standard protocol, as
previously described (9).
Statistical Analysis
All comparisons between the two groups were performed using
Mann-Whitney U-tests and Fisher’s exact probability tests for
continuous and categorical variables, respectively. Jonckheere-
Terpstra Test was performed to clarify the relationship between
MIBG uptake and frequency of falls. For trend analysis, the
subjects were divided into three groups according to MIBG
uptake (group 1, delayed H/M ratio< 1.8; group 2, 1.8≤ delayed
H/M ratio ≤ 2.7; group 3, 2.7 < delayed H/M ratio). Analyses
were performed using SPSS statistics software (IBM; Armonk,
NY). The predictive power of MIBG cardiac scintigraphy data
for falls was evaluated using Kaplan-Meier analysis. Survival
curves were compared using the log-rank test. This analysis was
computed using R software (http://www.r-project.org/). P < 0.05
were considered statistically significant.
TABLE 1 | Characteristics of patients with PD in the study.
Characteristics Decreased
uptake of





Male (n) 17 9 0.562
Age at onset 62.7 (9.9) 58.8 (15.5) 0.307
Age at evaluation 67.7 (9.0) 61.3 (15.1) 0.132
Disease duration (m) 49.5 (52.6) 31.7 (32.7) 0.203
Hoehn-Yahr stage 1.95 (0.81) 1.77 (0.64) 0.357
Follow-up period (m) 89.6 (16.4) 87.8 (19.2) 0.669
Daily levodopa dose (mg) 141.4 (180.3) 82.3 (106.5) 0.188
Use of dopamine agonist (n) 13 5 0.286
Early H/M ratio 1.63 (0.25) 2.52 (0.47) * <0.001
Delayed H/M ratio 1.35 (0.22) 2.60 (0.79) * <0.001
The results are shown as mean ± standard deviation.
*Indicates a significant difference between the group with decreased uptake of MIBG and
that without decreased uptake of MIBG.
PD, Parkinson’s disease; MIBG, 123 I-meta-iodobenzylguanidine; n, number; m, months;
H/M, heart-to-mediastinum.
RESULTS
We enrolled 45 patients with PD in this study based
on the inclusion criteria. Each step of the recruitment
process is presented in Supplementary Figure 1. The patient
characteristics are summarized in Table 1. There were no
significant differences in sex, age at onset, age at MIBG
evaluation, Hoehn-Yahr stage, follow-up period, daily levodopa
dose at MIBG evaluation, or use of dopamine agonist at MIBG
evaluation between the groups. The group with decreased uptake
of MIBG had a higher incidence of falls than the group without
decreased uptake of MIBG (P = 0.022, log-rank test; Figure 1).
Next, we investigated the effect of MIBG uptake on severity
and frequency of falls. There was no significant difference in
the incidence of severe falls between groups divided by MIBG
uptake (P = 0.081, log-rank test; Supplementary Figure 2A).
Frequency of falls was significantly associated with MIBG uptake
in the delayed phase (P = 0.017, Jonckheere-Terpstra test;
Supplementary Figure 2B).
DISCUSSION
An MIBG-defined imaging phenotype was demonstrated to
predict falls in patients with PD in the present study. This
supports the potential utility of MIBG as an objective biomarker
for prognosis of motor function.
The ideal biomarker is based on a risk factor that is a
continuous variable and easy to measure across institutes. MIBG
scintigraphy may be an easy and objective biomarker to predict
falls, as uptake is standardized using a phantom in this technique.
Another candidate biomarker is the β-amyloid 42 level in
cerebrospinal fluid, which is associated with gait progression (10).
A multifactorial model including MIBG uptake and β-amyloid
42 concentration could lead to development of a biomarker for
prediction of falls.
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FIGURE 1 | Cumulative fall-free survival based on delayed
heart-to-mediastinum ratio (H/M ratio) was shown. The group with decreased
uptake of 123 I-meta-iodobenzylguanidine (MIBG) (n = 29, delayed H/M
ratio < 1.8) and the group without decreased uptake of MIBG (n = 16,
delayed H/M ratio ≥ 1.8).
Reduced MIBG uptake has been reported to be related to
dementia and hallucination (6, 11). Motor dual-tasking deficits
may predict falls (12), and cholinesterase inhibitors, which
are used to treat cognitive impairment, have been reported
to improve gait stability (2). Taken together, multiple lines
of evidence suggest the presence of a significant association
between cognitive function and falls. Considering that both
regular falls and cognitive impairment may determine time to
death (13), reduced MIBG uptake might predict an unfavorable
prognosis in PD. Decreased cardiac uptake of MIBG reflects
degeneration of postganglionic presynaptic nerve terminals in
the adrenergic nervous system, where the presence of alpha-
synuclein aggregates has been pathologically confirmed (14).
It is reasonable that orthostatic hypotension is implicated in
falls, and that falls are alleviated by droxidopa, which is a
prodrug of norepinephrine (3). The relationship between MIBG
scintigraphy and falls is understandable, as reduced uptake
of MIBG reflects autonomic dysfunction, including orthostatic
hypotension. Although MIBG uptake has been reported to be
heterogeneous in PD (7), a significant reduction in MIBG uptake
might indicate that alpha-synuclein aggregates are distributed
widely in the whole body, including the brain. That said, in terms
of pathology, decreased uptake of MIBG might be considered as
a poor prognostic factor, which was further supported by clinical
evidence that decreased uptake of MIBG was associated with
cognitive impairment, hallucination, autonomic dysfunction and
REM sleep behavior disorder (15). This study adds falls to the
above-mentioned list.
The most important subtype of falls from the viewpoint of
prognosis is thought to be recurrent/regular falls. Falls have been
classified into two subtypes: falling forward and falling backward
or sideways. The subtypes are thus based on the direction
of the fall, which is reflective of the mechanism underlying
each type of fall (16). However, it remains unknown whether
there are differences in MIBG uptake and other factors between
these subtypes.
The limitations of our study are moderate number of subjects
and the use of univariate analysis due to lack of several key
factors including cognitive assessment, autonomic function test,
gait freezing, motor score, direction of the fall and the relation
between falls and drugs, which may have biased the results.
Future investigation will be carried out in a prospective cohort
using multivariate analysis. This will allow us to adjust for
confounders, such as age, sex, disease duration, disease severity,
levodopa equivalent dose, mood, hallucination, dementia, and
types of falls.
In summary,MIBG scintigraphymay predict motor prognosis
as well as cognitive prognosis in patients with PD. Further
prospective studies are needed to validate the present findings
using multivariate analysis.
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Supplementary Figure 1 | A flow diagram for the present study was shown. The
diagram illustrates the inclusion and exclusion criteria used. Data from forty-five
subjects with Parkinson’s disease were analyzed. PD, Parkinson’s disease; MIBG,
123 I-meta-iodobenzylguanidine.
Supplementary Figure 2 | Cumulative severe fall-free survival based on delayed
heart-to-mediastinum ratio (H/M ratio) was shown (A). The group with decreased
uptake of 123 I-meta-iodobenzylguanidine (MIBG) (n = 29, delayed
H/M ratio < 1.8) and the group without decreased uptake of MIBG (n = 16,
delayed H/M ratio ≥ 1.8). The relationship between delayed H/M ratio and
frequency of falls were shown (B). The subjects were divided into three groups
according to MIBG uptake (group 1, delayed H/M ratio < 1.8;
group 2, 1.8 ≤ delayed H/M ratio ≤ 2.7; group 3, 2.7 < delayed H/M ratio).
Supplementary Table 1 | Injuries due to falls and the number of subjects.
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